PL1716152T3 - Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych - Google Patents

Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych

Info

Publication number: PL1716152T3
Authority: PL; Poland
Prior art keywords: sup; gastrointestinal disorders; treatment; receptor antagonists; metabotropic receptor
Prior art date: 2004-02-18

Application number

PL05713794T

Other languages

English (en)

Inventor

Martin Johansson

David Wensbo

Alexander Minidis

Karin Staaf

Annika Kers

Louise Edwards

Methvin Isaac

Tomislav Stefanac

Abdelmalik Slassi

Donald Mcleod

Tao Xin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-18

Filing date

2005-02-17

Publication date

2009-01-30

2005-02-17 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2009-01-30 Publication of PL1716152T3 publication Critical patent/PL1716152T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)

PL05713794T 2004-02-18 2005-02-17 Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych PL1716152T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US54528804P	2004-02-18	2004-02-18
US54558004P	2004-02-19	2004-02-19
EP05713794A EP1716152B1 (en)	2004-02-18	2005-02-17	Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
PCT/US2005/005218 WO2005080397A2 (en)	2004-02-18	2005-02-17	Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders

Publications (1)

Publication Number	Publication Date
PL1716152T3 true PL1716152T3 (pl)	2009-01-30

Family

ID=34886171

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05713794T PL1716152T3 (pl)	2004-02-18	2005-02-17	Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych

Country Status (21)

Country	Link
US (1)	US20070185095A1 (pl)
EP (1)	EP1716152B1 (pl)
JP (1)	JP2007523183A (pl)
KR (1)	KR20070026380A (pl)
CN (1)	CN1934112A (pl)
AT (1)	ATE402935T1 (pl)
BR (1)	BRPI0507495A (pl)
CA (1)	CA2556320A1 (pl)
DE (1)	DE602005008558D1 (pl)
DK (1)	DK1716152T3 (pl)
ES (1)	ES2309718T3 (pl)
HR (1)	HRP20080480T3 (pl)
IL (1)	IL177291A0 (pl)
MY (1)	MY152888A (pl)
PL (1)	PL1716152T3 (pl)
PT (1)	PT1716152E (pl)
RU (1)	RU2006129324A (pl)
SI (1)	SI1716152T1 (pl)
UA (1)	UA82435C2 (pl)
WO (1)	WO2005080397A2 (pl)
ZA (1)	ZA200606508B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20050033070A (ko)	2002-08-09	2005-04-08	아스트라제네카 에이비이	메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
US7807706B2 (en)	2005-08-12	2010-10-05	Astrazeneca Ab	Metabotropic glutamate-receptor-potentiating isoindolones
AR058807A1 (es)	2005-09-29	2008-02-27	Astrazeneca Ab	5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
TW200811179A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators VI
TW200811157A (en)	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators I
TW200808800A (en) *	2006-05-05	2008-02-16	Astrazeneca Ab	MGluR5 modulators V
JPWO2008078725A1 (ja) *	2006-12-26	2010-04-30	第一三共株式会社	チアゼピン誘導体
TW200911255A (en) *	2007-06-07	2009-03-16	Astrazeneca Ab	Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) *	2007-06-07	2013-12-01	Astrazeneca Ab	二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200922586A (en) *	2007-10-26	2009-06-01	Astrazeneca Ab	Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054786A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
WO2009054792A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Aminopyridine derivatives as modulators of mglur5
WO2009054789A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
WO2009054791A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
US7790760B2 (en)	2008-06-06	2010-09-07	Astrazeneca Ab	Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
CN102666535B (zh)	2009-11-30	2015-02-25	诺华股份有限公司	作为醛固酮合酶抑制剂的咪唑衍生物
CA2784768C (en)	2009-12-29	2015-02-03	Eli Lilly And Company	Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102762572A (zh)	2010-02-01	2012-10-31	诺瓦提斯公司	作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
JP5748777B2 (ja)	2010-02-02	2015-07-15	ノバルティスアーゲー	Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
MX342161B (es)	2010-04-02	2016-09-19	Euroscreen Sa	Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
US10065960B2 (en)	2010-04-02	2018-09-04	Ogeda Sa	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
JP2013525427A (ja) *	2010-04-30	2013-06-20	アストラゼネカ・アクチエボラーグ	代謝調節型グルタミン酸受容体ポジティブアロステリックモジュレーターの多形
CN103906750B9 (zh) *	2011-10-03	2016-10-12	欧洲筛选有限公司	作为选择性NK-3受体拮抗剂的新型手性N-酰基-5,6,7,(8-取代的)-四氢-[1，2,4]三唑并[4，3-a]吡嗪、药物组合物、用于NK-3受体介导的疾病中的方法及其手性合成
ES2646488T3 (es)	2013-03-29	2017-12-14	Ogeda S.A.	N-acil-(3-sustituido)-(8-sustituido)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para uso en trastornos mediados por el receptor NK-3
CA2907814C (en)	2013-03-29	2021-07-13	Euroscreen Sa	Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
US10183948B2 (en)	2013-03-29	2019-01-22	Ogeda Sa	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
CA2907813C (en)	2013-03-29	2021-09-07	Euroscreen Sa	Novel n-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
GB201312800D0 (en) *	2013-07-17	2013-08-28	Heptares Therapeutics Ltd	mGlu5 modulators
MX367633B (es)	2014-09-25	2019-08-29	Ogeda S A	Nueva sintesis quiral de n-acil-(3-sustituidas)-(8-sustituidas)-5, 6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK2512002A3 (en) *	1999-08-19	2002-07-02	Nps Pharma Inc	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2003264018A1 (en) *	2002-08-09	2004-02-25	Astrazeneca Ab	Compounds having an activity at metabotropic glutamate receptors

2005
- 2005-02-17 EP EP05713794A patent/EP1716152B1/en not_active Expired - Lifetime
- 2005-02-17 DE DE602005008558T patent/DE602005008558D1/de not_active Expired - Fee Related
- 2005-02-17 DK DK05713794T patent/DK1716152T3/da active
- 2005-02-17 US US10/588,699 patent/US20070185095A1/en not_active Abandoned
- 2005-02-17 RU RU2006129324/04A patent/RU2006129324A/ru not_active Application Discontinuation
- 2005-02-17 WO PCT/US2005/005218 patent/WO2005080397A2/en not_active Ceased
- 2005-02-17 UA UAA200608820A patent/UA82435C2/uk unknown
- 2005-02-17 BR BRPI0507495-9A patent/BRPI0507495A/pt not_active IP Right Cessation
- 2005-02-17 CN CN200580008454.2A patent/CN1934112A/zh active Pending
- 2005-02-17 KR KR1020067015826A patent/KR20070026380A/ko not_active Withdrawn
- 2005-02-17 MY MYPI20050602 patent/MY152888A/en unknown
- 2005-02-17 PL PL05713794T patent/PL1716152T3/pl unknown
- 2005-02-17 ES ES05713794T patent/ES2309718T3/es not_active Expired - Lifetime
- 2005-02-17 PT PT05713794T patent/PT1716152E/pt unknown
- 2005-02-17 JP JP2006554237A patent/JP2007523183A/ja not_active Withdrawn
- 2005-02-17 CA CA002556320A patent/CA2556320A1/en not_active Abandoned
- 2005-02-17 HR HR20080480T patent/HRP20080480T3/xx unknown
- 2005-02-17 AT AT05713794T patent/ATE402935T1/de not_active IP Right Cessation
- 2005-02-17 SI SI200530394T patent/SI1716152T1/sl unknown
2006
- 2006-08-03 IL IL177291A patent/IL177291A0/en unknown
- 2006-08-04 ZA ZA200606508A patent/ZA200606508B/en unknown

Also Published As

Publication number	Publication date
JP2007523183A (ja)	2007-08-16
HRP20080480T3 (hr)	2008-11-30
RU2006129324A (ru)	2008-04-10
WO2005080397A2 (en)	2005-09-01
PT1716152E (pt)	2008-10-02
SI1716152T1 (sl)	2008-12-31
HK1098460A1 (en)	2007-07-20
IL177291A0 (en)	2006-12-10
MY152888A (en)	2014-11-28
KR20070026380A (ko)	2007-03-08
ES2309718T3 (es)	2008-12-16
US20070185095A1 (en)	2007-08-09
DK1716152T3 (da)	2008-11-03
WO2005080397A8 (en)	2006-06-22
ATE402935T1 (de)	2008-08-15
ZA200606508B (en)	2007-11-28
CN1934112A (zh)	2007-03-21
EP1716152B1 (en)	2008-07-30
CA2556320A1 (en)	2005-09-01
BRPI0507495A (pt)	2007-07-10
EP1716152A2 (en)	2006-11-02
DE602005008558D1 (de)	2008-09-11
UA82435C2 (uk)	2008-04-10
WO2005080397A3 (en)	2005-12-22

Publication	Publication Date	Title
PL1716152T3 (pl)	2009-01-30	Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
EA200601266A1 (ru)	2007-02-27	Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
DE602005020655D1 (de)	2010-05-27	Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
WO2003028641A3 (en)	2003-08-28	Mch receptor antagonists
ATE423769T1 (de)	2009-03-15	Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
EA200700099A1 (ru)	2007-08-31	Производные пиридина
EA200900658A1 (ru)	2009-12-30	Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
TW200505903A (en)	2005-02-16	CGRP receptor antagonists
ATE466860T1 (de)	2010-05-15	Cgrp-rezeptorantagonisten
SE0303180D0 (sv)	2003-11-26	Novel compounds
SE0302232D0 (sv)	2003-08-18	Novel Compounds
EA200501595A1 (ru)	2006-06-30	Азабициклические производные в качестве антагонистов мускаринового рецептора
SE0302760D0 (sv)	2003-10-20	New compounds
CY1109808T1 (el)	2014-09-10	Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
DE602004005960D1 (de)	2007-05-31	Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
TW200720260A (en)	2007-06-01	Prokineticin 1 receptor antagonists
DE602005027230D1 (de)	2011-05-12	Cgrp-rezeptorantagonisten
TW200716566A (en)	2007-05-01	Prokineticin 2 receptor antagonists
EA200501593A1 (ru)	2006-06-30	Азабициклические производные в качестве антагонистов мускаринового рецептора
EA200501594A1 (ru)	2006-08-25	Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
DE602005009512D1 (de)	2008-10-16	3-((hetero)arylsulfonyl)-8-ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns
MX2007000576A (es)	2007-06-25	Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
NO20063562L (no)	2006-11-06	Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
DE602005018916D1 (de)	2010-03-04	Vanilloidrezeptor trpv1-antagonisten
MX2007004535A (es)	2007-06-08	Antagonistas de integrinas bifenilicos.